|
|
|
 |
|
|
|
|
Cognitive Function and Hormone Therapy in Advanced Prostate Cancer
Conversation with Alicia Morgans
and Charles Ryan
|
|
|
|
|
COGCaP: An Investigation into the Cognitive Side Effects of Androgen Receptor Targeted Therapies
Written By: Alicia Morgans
Whether androgen deprivation therapy (ADT) affects the cognitive function of men with prostate cancer remains controversial. While some studies have demonstrated that ADT impairs cognitive function, other studies have not found any such association.
|
|
|
Adverse effects of ADT on cognitive function and dementia for men with prostate cancer: A meta-analysis and systematic review
Androgen deprivation therapy (ADT) is a common treatment for metastatic hormone-sensitive prostate cancer. Over 500,000 men are current on an ADT regimen. However, ADT does have some notable side-effects.
|
|
|
ADT for prostate cancer and dementia risk- PCAN Full Text Article
Androgen deprivation therapy (ADT) is a mainstay of treatment for metastatic and locoregional prostate cancer. Globally, there are over a million new diagnoses of prostate cancer each year and an estimated 50% of men with prostate cancer will ultimately utilize ADT. Therefore, the potential individual and health system implications of adverse effects of ADT are significant.
|
|
|
From the Desk of the Associate Editor: Androgen deprivation therapy for prostate cancer and dementia risk: a systematic review and meta-analysis
Androgen deprivation therapy causes a host of well-recognized side effects. Recent epidemiological and clinical evidence suggests that ADT may also be associated with dementia and cognitive impairment.
|
|
|
A Randomized Phase II Trial of Ascorbic Acid in Combination with Docetaxel in Men with Metastatic Prostate Cancer
Ascorbic acid (vitamin C) is being used by complementary medicine practitioners to treat cancer, infections, and other conditions. Annual administration of more than 355,000 doses of intravenous (I.V.) ascorbic acid for more than 10,000 patients has been documented. Phase I and II clinical trials in 2012, 2013, and 2014 demonstrated safety and anti-tumor activity for high dose I.V. ascorbic acid.
|
|
|
ASCO 2017: Physical and Cognitive Effects of Systemic Therapy in Older Men with Prostate Cancer
Dr. Alicia Morgans from Vanderbilt University concluded the “Disparities in Screening and Treatment of Prostate Cancer for the Older Patient” session at the 2017 ASCO meeting with an excellent talk regarding the physical and cognitive effects of systemic therapy in older men with prostate cancer.
|
|
|
|
|
Cognitive Effects of Androgen Receptor (AR) Directed Therapies for Advanced Prostate Cancer
This clinical trial studies cognitive function in men with prostate cancer treated with androgen receptor directed therapies such as abiraterone acetate and enzalutamide.
|
|
|
The Impact of Androgen Ablation Therapy on Cognitive Functioning and Functional Status in Men with Prostate Cancer Age 65 and Older
The purpose of this study is to find out if therapy with hormones (such as Lupron, Casodex, Zolodex or Degarelix) change a person's thinking abilities.
|
|
|
|
|
Cognitive impairment following hormone therapy: current opinion of research in breast and prostate cancer patients.
Hormone therapy is a common cancer treatment that may be associated with numerous side and late effects, and in recent years, has been linked to changes in cognition.
|
|
|
Impact of new generation hormone-therapy on cognitive function in elderly patients treated for a metastatic prostate cancer: Cog-Pro trial protocol.
New generation hormone-therapies targeting the androgen signaling pathway are nowadays proposed to elderly patients with metastatic castration-resistant prostate cancer.
|
|
|
|
|
|
